Загрузка...
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor...
Сохранить в:
| Опубликовано в: : | Mol Cancer |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5817870/ https://ncbi.nlm.nih.gov/pubmed/29455650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0777-1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|